Phase 1 Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies

Trial Profile

Phase 1 Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs PFK 158 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Advanced Cancer Therapeutics
  • Most Recent Events

    • 22 Jun 2015 According to the ClinicalTrials.gov record, planned number of patients changed from 54 to 56.
    • 22 Jun 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Jun 2015 to 1 Sep 2015.
    • 27 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top